The Global Burden of Viral Hepatitis 1990-2013

Background: With recent improvements in vaccines and treatments against viral hepatitis, a better understanding of the burden of viral hepatitis is needed to inform global intervention strategies. We present estimates from the Global Burden of Disease (GBD) Study of morbidity and mortality for acute viral hepatitis, and for cirrhosis and liver cancer due to viral hepatitis by age, sex and country for 1990 through 2013. Methods: Mortality was estimated using natural history models for acute hepatitis and GBD’s cause-of-death ensemble model for cirrhosis and liver cancer. We estimated disease prevalence, and liver cancer and cirrhosis aetiologies via meta-regression. Disability adjusted life-years (DALYs) were calculated as the sum of years of life lost (YLLs) and years lived with disability (YLDs). Findings: Between 1990 and 2013, viral hepatitis deaths increased from 0·90 million (95% uncertainty interval 0·86 – 0·94) to 1·45 million (1·38–1·54); YLLs increased from 31·0 million (29·6–32·6) to 41·6 million (39·1–44·7); YLDs, from 0·65 million (0·45–0·89) to 0·87 million (0·61–1·18); and DALYs, from 31·7 million (30·2– 33·3) to 42·5 million (39·9–45·6). In 2013, viral hepatitis was the 7 leading cause of death globally. Interpretation: Viral hepatitis is a leading cause of death and disability worldwide. Unlike most communicable diseases, between 1990 and 2013, viral hepatitis has increased in terms of both absolute burden and its relative rank. Funding: Bill and Melinda Gates Foundation

[1]  Gérard Krause,et al.  Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013 , 2015, The Lancet.

[2]  Nobhojit Roy,et al.  The Global Burden of Cancer 2013. , 2015, JAMA oncology.

[3]  Dan J Stein,et al.  Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013 , 2015, The Lancet.

[4]  G. Cooke,et al.  Long-Term Treatment Outcomes of Patients Infected With Hepatitis C Virus: A Systematic Review and Meta-analysis of the Survival Benefit of Achieving a Sustained Virological Response , 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[5]  T. Vos,et al.  Assessing disability weights based on the responses of 30,660 people from four European countries , 2015, Population Health Metrics.

[6]  Bernadette A. Thomas,et al.  Global, regional, and national age–sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013 , 2015, The Lancet.

[7]  N. Ford,et al.  Viral hepatitis and the Global Burden of Disease: a need to regroup , 2013, Journal of viral hepatitis.

[8]  John McNally,et al.  Sofosbuvir for previously untreated chronic hepatitis C infection. , 2013, The New England journal of medicine.

[9]  A. Flaxman,et al.  Global epidemiology of hepatitis C virus infection: New estimates of age‐specific antibody to HCV seroprevalence , 2013, Hepatology.

[10]  T. Pilot‐Matias,et al.  Exploratory study of oral combination antiviral therapy for hepatitis C. , 2013, The New England journal of medicine.

[11]  Mohsen Naghavi,et al.  GBD 2010: design, definitions, and metrics , 2012, The Lancet.

[12]  Gretchen A. Stevens,et al.  The global burden of hepatitis E virus genotypes 1 and 2 in 2005 , 2012, Hepatology.

[13]  Gretchen A. Stevens,et al.  Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. , 2012, Vaccine.

[14]  J. Salomon New disability weights for the global burden of disease. , 2010, Bulletin of the World Health Organization.

[15]  K. Jacobsen,et al.  Hepatitis A virus seroprevalence by age and world region, 1990 and 2005. , 2010, Vaccine.

[16]  L. Finelli,et al.  Cost-Effectiveness of Routine Childhood Vaccination for Hepatitis A in the United States , 2007, Pediatrics.

[17]  Xiaomei Ma,et al.  Global Burden of Cancer , 2006, The Yale journal of biology and medicine.

[18]  Jennifer A. Roberts,et al.  Health benefits of antiviral therapy for mild chronic hepatitis C: randomised controlled trial and economic evaluation. , 2006, Health technology assessment.

[19]  P. Lopalco,et al.  Case fatality rate of acute viral hepatitis in Italy: 1995-2000. An update. , 2003, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[20]  B. Bell,et al.  Hepatitis A virus infections in the United States: model-based estimates and implications for childhood immunization. , 2002, Pediatrics.

[21]  T. Wright,et al.  Acute hepatitis C , 2001, Hepatology.

[22]  L. Seeff,et al.  Natural history of hepatitis C , 1997, Hepatology.

[23]  T R Bender,et al.  Acute hepatitis B virus infection: relation of age to the clinical expression of disease and subsequent development of the carrier state. , 1985, The Journal of infectious diseases.

[24]  M. Dickie,et al.  Global Health Sector Strategy on Viral Hepatitis : What does it mean for Canadians ? , 2018 .

[25]  P. Marcellin,et al.  Hepatitis C: the clinical spectrum of the disease. , 1999, Journal of hepatology.

[26]  E. Balocchini,et al.  Case fatality rate of acute hepatitis in Italy: results from a 10 year surveillance. , 1997, Scandinavian journal of infectious diseases.

[27]  R. W. Mccollum The natural history of hepatitis. , 1969, Bulletin of the New York Academy of Medicine.

[28]  J. Herrera,et al.  Hepatitis E virus infection , 2018, Nature Reviews Disease Primers.